Journal article icon

Journal article

Effect of the proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab on glycemia, body weight, and new-onset diabetes mellitus

Abstract:

Statin therapy modestly increases new-onset diabetes risk. The effect of PCSK9 inhibition on new-onset diabetes, glycemia and weight remains unclear.We studied the effects of the PCSK9 inhibitor evolocumab on fasting plasma glucose [FPG], glycated hemoglobin (HbA1c), weight and new-onset diabetes mellitus. We pooled 1-year (48-week) data for participants who had completed an evolocumab parent study before entering an open-label extension (OLE) trial. Data were available for 4,802 participants...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1016/j.amjcard.2017.07.047

Authors


Expand authors...
Publisher:
Elsevier Publisher's website
Journal:
American Journal of Cardiology Journal website
Volume:
120
Issue:
9
Pages:
1521-1527
Publication date:
2017-07-31
Acceptance date:
2017-07-21
DOI:
EISSN:
1879-1913
ISSN:
0002-9149
Pubs id:
pubs:710879
URN:
uri:18f08523-bed9-4470-bb04-11e18a4c0abe
UUID:
uuid:18f08523-bed9-4470-bb04-11e18a4c0abe
Local pid:
pubs:710879
Paper number:
9

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP